Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5635365 | 0.98 | SLC6A2 (0.33) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| Hydrochloric Acid SCHEMBL1873378 | 0.98 | SLC6A2 (0.33) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL11530932 | 0.88 | CHRM1 (0.37) | SLC6A2SLC6A4SLC6A3RET | |
| SCHEMBL31209837 | 0.88 | CHRM1 (0.37) | SLC6A2SLC6A4SLC6A3RET | |
| SCHEMBL31209754 | 0.88 | CHRM1 (0.37) | SLC6A2SLC6A4SLC6A3RET | |
| SCHEMBL6448975 | 0.85 | ALDH1A1 (0.39) | SLC6A2HTR2AHTR2CSLC6A4HTR7 | |
| SCHEMBL31495554 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL4010515 | 0.84 | SLC6A2 (0.33) | SLC6A2SLC6A4HRH3 | |
| SCHEMBL12832331 | 0.80 | NPC1 (0.39) | RET | |
| SCHEMBL8376331 | 0.78 | NPC1 (0.47) | RETHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0614664-B2 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | claimed |
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | disclosed |
| CN-114728917-B | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-114728914-B | Dioxopiperazine derivative, preparation method thereof and application thereof in medicines | 深圳信立泰药业股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-01-26 | — | — | US | disclosed |
| EP-4050006-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2022-08-31 | — | — | EP | disclosed |
| CN-114945562-A | Bicyclic compounds and uses thereof | 爱思开生物制药株式会社 | 2022-08-26 | — | — | CN | disclosed |
| CN-114728917-A | Oxamide derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728914-A | Dioxopiperazine derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009082346-A1 | NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| EP-0614664-B2 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | disclosed |
| US-5889009-A | ADMINISTERING 1,7-DISUBSTITUTED-4-OX-3-(QUINOLINECARBOXYLIC ACID OR NAPHTHYRIDINECARBOXYLIC ACID) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | disclosed |
| US-5703081-A | CELL ADHESION INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| US-5519024-A | CELL ADHESION INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | disclosed |
| EP-0614664-A1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023140-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | SLC6A2 4810/4885HTR2A 4489/4885HTR2C 4294/4885 |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | SLC6A2 4760/4885HTR2A 2226/4885HTR2C 1023/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | SLC6A2 4810/4885HTR2A 4489/4885HTR2C 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.